^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cibisatamab (RG7802)

    i
    Other names: RG7802, RG-7802, RO6958688, CEA-TCB, RO 6958688, RO-6958688, CEA-CD3 TCB, WHO 10636
    Associations
    News

    Trials

    Company:
    Roche
    Drug class:
    CD3 agonist, CEA inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (Morpheus Lung) (NCT03337698)
    Phase 1/2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    12/27/2017
    Primary completion :
    09/30/2025
    Completion :
    11/30/2026
    PD-L1
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • docetaxel • Cotellic (cobimetinib) • pemetrexed • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Repatha (evolocumab) • camonsertib (RP-3500) • cibisatamab (RG7802) • ciforadenant (CPI-444) • zanzalintinib (XL092)
    Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment (BP42675) (NCT04826003)
    Phase 1/2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    06/06/2024
    Initiation :
    07/14/2021
    Primary completion :
    12/27/2024
    Completion :
    12/27/2024
    CEACAM5
    |
    CEACAM5 expression • CEACAM5 overexpression
    |
    Gazyva (obinutuzumab) • RG7827 • cibisatamab (RG7802)
    A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma (NCT03866239)
    Phase 1
    Hoffmann-La Roche
    Completed
    Last update posted :
    03/15/2024
    Initiation :
    05/07/2019
    Primary completion :
    03/13/2024
    Completion :
    03/13/2024
    MSI • CEACAM5
    |
    Tecentriq (atezolizumab) • Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • cibisatamab (RG7802)
    A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors (NCT02324257)
    Phase 1
    Hoffmann-La Roche
    Completed
    Last update posted :
    04/17/2020
    Initiation :
    12/30/2014
    Primary completion :
    09/03/2019
    Completion :
    09/03/2019
    CEACAM5
    |
    CEACAM5 expression
    |
    Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • cibisatamab (RG7802)
    A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors (NCT02650713)
    Phase 1
    Hoffmann-La Roche
    Completed
    Last update posted :
    02/12/2020
    Initiation :
    01/07/2016
    Primary completion :
    01/13/2020
    Completion :
    01/13/2020
    CEACAM5
    |
    CEACAM5 expression
    |
    Tecentriq (atezolizumab) • cibisatamab (RG7802)